Updates and corrections
What we changed after first publishing, newest first: new facts or filings, corrections, and Long View updates after earnings. Each link goes to the update in the article. Closing-price refreshes are not listed. See our corrections policy.
- Anthropic closes 17% above its IPO price after opening 34% higher in its Nasdaq debut
The IPO closed on Nov 20 with all 147 million option shares: 1.127 billion shares, about $93.5 billion before fees.
- The trillion-dollar AI IPOs: what the valuations would have to prove
Our Nov 18 update called about $1.1 trillion the value at $83 of "the shares outstanding after the deal" without saying that this legal…
- Anthropic sets its IPO price at $83, topping the $70–78 range
Our Nov 18 update and earlier text described about $1.1 trillion at $83 as the value of "the shares outstanding after the deal" without…
- Anthropic sets its IPO price at $83, topping the $70–78 range
Anthropic is now listed on Nasdaq as ANT; the final prospectus gives its share count and about $104.8 billion of net proceeds.
- Meta lines up $97.5 billion of stock sales, before options, to fund its AI build-out
Meta agreed not to issue Class C shares through the trial of a Delaware lawsuit, proposed for April 2027.
- Summit Therapeutics: One Man, One Drug and a $500 Million Check
Updated: Akeso's account, its share fall and share purchases, the FDA's 60% figure and 2015 finding, and HARMONi-10.
- The trillion-dollar AI IPOs: what the valuations would have to prove
Anthropic priced its IPO at $83, above its range: about $1.1 trillion by our calculation, about $175 billion of revenue on our first test.
- The trillion-dollar AI IPOs: what the valuations would have to prove
Updated Nov 18, 2026: after Anthropic's pricing, the number card now shows the value at $83 (about $1.1 trillion, our calculation) instead of the $1.2–1.3…
- Anthropic sets its IPO price at $83, topping the $70–78 range
Anthropic priced its IPO at $83 a share, above its $70–78 range, and sold 980 million shares for $81.3 billion.
- Corcept Therapeutics (CORT): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 3, 2026.
- Xencor (XNCR): The Long View
Net cash is $486.4M, not $381.5M, and enterprise value $1,683M, not $1,788M (EV/sales 16.0×, not 17.0×).
- Xencor (XNCR): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 4, 2026.
- Anthropic sets its IPO price at $83, topping the $70–78 range
Anthropic expects to price its IPO on Nov 18 and start trading Nov 19; FT says bankers weigh a higher price.
- Nvidia: our view and what our model says about 2030
Nov 12: Jensen Huang resigned as CEO; Colette Kress is interim CEO. We'll review this view after the Nov 17 results.
- Nvidia without Jensen Huang: his grip, the missing heir and history
Nvidia said Thursday morning that its board had accepted Jensen Huang's resignation as president, chief executive and director on Nov 11, effective…
- Arrowhead Pharmaceuticals (ARWR): The Long View
Updated for the 10-K for the fiscal year to Sep 30, 2026, filed Nov 12, 2026.
- Instacart (Maplebear) (CART): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 5, 2026.
- CoStar Group (CSGP): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Oct 28, 2026.
- Fortinet (FTNT): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Oct 30, 2026.
- Genmab (GMAB): The Long View
Updated for the 20-F for the fiscal year to Dec 31, 2025.
- Alphabet (GOOGL): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Oct 29, 2026.
- IDEXX Laboratories (IDXX): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 2, 2026.
- Illumina (ILMN): The Long View
Updated for the 10-Q for the quarter to Sep 27, 2026, filed Oct 30, 2026.
- Immunocore (IMCR): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 6, 2026.
- Innodata (INOD): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 5, 2026.
- Iovance Biotherapeutics (IOVA): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 5, 2026.
- Moderna (MRNA): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 6, 2026.
- Rocket Lab (RKLB): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 9, 2026.
- Sea Limited (SE): The Long View
Updated for the 20-F for the fiscal year to Dec 31, 2025, filed Apr 17, 2026.
- Tango Therapeutics (TNGX): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 9, 2026.
- GeneDx Holdings (WGS): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 9, 2026.
- Nvidia without Jensen Huang: his grip, the missing heir and history
The Wall Street Journal reported Wednesday that Nvidia's board was preparing to remove CEO Jensen Huang; Reuters and CNN, citing sources, reported that it was…
- Agios Pharmaceuticals (AGIO): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 5, 2026.
- Hims & Hers (HIMS): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 9, 2026.
- TG Therapeutics (TGTX): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 9, 2026.
- Vera Therapeutics (VERA): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 5, 2026.
- Firefly jumps about 37% on a $1.3B engine deal with AST SpaceMobile
Firefly's finance chief said AST deal revenue will start in earnest in 2027; Firefly raised the bottom of its 2026 revenue range.
- TG Therapeutics Q3 2026: Briumvi target raised again, but sales growth slows to 2% from Q2
Updated with the 10-Q, filed after the close on Nov 9: Q3 revenue also included a $5.0 million payment from partner Neuraxpharm, and some of TG's imported drug…
- Anthropic sets its IPO price at $83, topping the $70–78 range
Anthropic set a $70–78 IPO range for 825 million shares and a $26.0 billion partner placement; CNBC reports pricing on Nov 18.
- Shorter belts, smaller plates: how GLP-1 drugs are reaching far beyond pharma
FDA, Nov 9: all GLP-1 drugs, including Zepbound and Foundayo, must warn of a rare eye condition, NAION.
- TG Therapeutics Q3 2026: Briumvi target raised again, but sales growth slows to 2% from Q2
Updated to the Nov 9 close: the shares closed up 5.9% at $63.38 after falling as much as about 9% in the morning; an earlier version gave the early-afternoon…
- Nvidia: our view and what our model says about 2030
Nvidia's board opened an independent investigation and said it had confidence in Jensen Huang and his leadership team.
- The trillion-dollar AI IPOs: what the valuations would have to prove
Buyers reportedly discussed $1.2–1.3 trillion for Anthropic on Nov 6; OpenAI closed $11 billion at $1.25 trillion.
- The trillion-dollar AI IPOs: what the valuations would have to prove
Updated Nov 7, 2026: after Bloomberg's Nov 6 report, the reported valuation in the title, summary, number card, status table and short version now includes the…
- Anthropic sets its IPO price at $83, topping the $70–78 range
Bloomberg: IPO buyers discussed $1.2–1.3 trillion on Nov 6, down from about $1.4–1.5 trillion; no price range filed yet.
- Anthropic sets its IPO price at $83, topping the $70–78 range
Updated Nov 7, 2026: What to watch now compares the coming price range with the $1.2–1.3 trillion buyers were discussing on Nov 6 (Bloomberg) as well as the…
- Coinbase Q3 2026: revenue flat at $1.2 billion as costs fall and a crypto gain lifts profit
Updated: without the $715.0M crypto gain, Q3 pretax profit would have been about $109M.
- Kyndryl jumps 30% as deal signings surge, though revenue fell
Updated: the second-quarter 10-Q had been filed when this article was published.
- iRhythm falls 31% as FDA filing slips and its raise leans on an acquisition
The path of the fall: the earlier version said about 28% near the open.
- Alnylam Pharmaceuticals (ALNY): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Oct 29, 2026.
- Astera Labs (ALAB): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 4, 2026.
- Madrigal Pharmaceuticals (MDGL): The Long View
Corrected: adds a disputed whistleblower-retaliation complaint disclosed in the Q3 10-Q.
- Madrigal: our view and what our model says about 2030
Corrected the legal table: it now shows a former employee's whistleblower-retaliation complaint from October, which Madrigal disputes.
- Madrigal Q3 2026: first profit and a sales beat, yet shares end 8% lower
Updated at the close: the shares reversed an early 11% gain and ended 8.1% lower.
- Alnylam Q3 2026: shares fall 25%; US demand adds less revenue than in Q2
Corrected: outlets named for target changes; CFO's low-end TTR guidance added; snapshot tax and debt notes fixed.
- GE Vernova sinks 11% in an AI power selloff after Meta's spending scare
Corrected: no company announcement explained the move; session low $813.26; Meta's capex and share-class facts; attributions; snapshot cash.
- Alphabet falls 13% as cash burn and a profit miss overshadow a cloud boom · also on: Long View
Share-count date corrected to the Oct 21 cover page; count and values unchanged.
- Madrigal Pharmaceuticals (MDGL): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 3, 2026.
- Palantir Technologies (PLTR): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Nov 3, 2026.
- Reddit falls 55% since July after warnings of weaker search traffic · also on: Long View
Share-count date corrected to the Oct 28 cover page; count and values unchanged.
- Anthropic sets its IPO price at $83, topping the $70–78 range
Anthropic filed an amended S-1 on Nov 2 that adds third-quarter results (SEC EDGAR).
- Arrowhead Pharmaceuticals (ARWR): The Long View
Debt now includes Arrowhead's credit line and Visirna's bank loan: debt $867.3M (was $682.7M), net cash $734.7M; EV $7.45B (was $7.27B).
- Illumina falls 19% even as it raises its full-year forecast · also on: Long View
Cash and investments now exclude $88M of equity securities and non-marketable investments; net debt and EV updated.
- Instacart (Maplebear) (CART): The Long View
Market value now uses 237.3M common shares after the Sep 21 preferred conversion: $14.4B (was $15.1B); EV recalculated.
- Madrigal Pharmaceuticals (MDGL): The Long View
Market value now uses 23.1M common shares, excluding convertible preferred and pre-funded warrants: $10.0B (was $12.6B).
- CATL falls 54% since June as taxes squeeze profit and customers move
Snapshot now uses the Shenzhen A-share, our standard line for CATL: market value CN¥1.077T (was CN¥1.375T).
- ORIC falls 32% after J&J shows early data for a rival prostate cancer drug · also on: Long View
Snapshot market value now uses 103.7M common shares: $929M (was $969M); enterprise value recalculated.
- Rocket Lab falls 64% since May in a space-stock rout and a Neutron delay · also on: Long View
Snapshot market value now uses 598.4M common shares: $32.2B (was $34.4B); EV and multiples recalculated.
- Xencor jumps 16% as its kidney cancer drug shrinks tumors in early trial
Snapshot market value now uses 74.4M common shares, excluding pre-funded warrants; EV and multiples recalculated.
- Meta lines up $97.5 billion of stock sales, before options, to fund its AI build-out
The $12.5 billion preferred sale closed on Oct 29, and the preferred is listed on Nasdaq as METAM (SEC 8-K and Form 8-A, Oct 29).
- Meta lines up $97.5 billion of stock sales, before options, to fund its AI build-out
Cash and investments now exclude $3.1 billion of equity stakes, so net debt and enterprise value rose by that amount.
- Nvidia: our view and what our model says about 2030 · also on: Long View
Cash and investments now total $56.6 billion; net cash is $23.2 billion, replacing net debt of $10.9 billion.
- Xencor jumps 16% as its kidney cancer drug shrinks tumors in early trial · also on: Long View
Cash and investments now total $486 million; net cash is $381 million; enterprise value is $1.84 billion.
- Instacart agrees to a $17 billion sale to DoorDash at $65 a share
Instacart's 8-K: $650M and $1.25B fees in specified cases and an Oct 28, 2027 end date; status and prices updated.
- Alnylam Pharmaceuticals (ALNY): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Oct 29, 2026.
- Coinbase (COIN): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Oct 29, 2026.
- Viking Therapeutics (VKTX): The Long View
Updated for the 10-Q for the quarter to Sep 30, 2026, filed Oct 29, 2026.
- Instacart agrees to a $17 billion sale to DoorDash at $65 a share
DoorDash and Instacart announced a signed merger agreement before the market opened on Oct 29.
- Anthropic sets its IPO price at $83, topping the $70–78 range
Bloomberg: Anthropic may reserve 15–20% of IPO shares for retail; Sen. Warren sent questions on S-1 risks.
- Instacart agrees to a $17 billion sale to DoorDash at $65 a share
CNBC: DoorDash's deal to buy Instacart could be announced as soon as Thursday morning; no deal filings by 5:15 p.m. ET.
- Instacart agrees to a $17 billion sale to DoorDash at $65 a share
The Wall Street Journal reported on Oct 26 that DoorDash is in advanced talks to buy Instacart, in a deal that could value it at about $17 billion.
- Tango Therapeutics falls 16% after pancreatic cancer trial update
Corrected errors, changed the headline, and added facts from Tango's Oct 23 SEC filing (8-K), which was filed before the market opened.
- CATL falls 54% since June as taxes squeeze profit and customers move
Added a line on the CYATY ADR and an FAQ on how CATL dividends reach ADR holders; clarified EU duties.
- The trillion-dollar AI IPOs: what the valuations would have to prove
Anthropic filed its prospectus (S-1) publicly with the SEC on Oct 26, for a Nasdaq listing under the ticker ANT.
- Moderna falls 18% as strong cancer-vaccine data misses sky-high hopes
The full results were presented at ESMO in Madrid on Oct 24 and matched the figures released on Oct 22.
- AI's borrowed boom: why 66 AI build-out stocks have lost about $2 trillion
Corrected the wording of a Dan Ives quote to match the interview transcript; the meaning is unchanged.
- AI's borrowed boom: why 66 AI build-out stocks have lost about $2 trillion
Corrected the ownership disclosure: one or more of our editors own Nvidia (NVDA), which this article mentions, as a long-term investment.